Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired coagulation inhibitor-associated bleeding disorders: an update.

Massimo Franchini1, Dino Veneri

  • 1Servizio di Immunoematologia e Trasfusione--Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy. mfranchini@mail.univr.it

Hematology (Amsterdam, Netherlands)
|December 3, 2005
PubMed
Summary

Acquired blood coagulation inhibitors are autoantibodies causing bleeding disorders in individuals without prior defects. This review covers recent advances in understanding, diagnosing, and treating these rare conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual case of sodium citrate-dependent artifactual platelet count.

Interventional medicine & applied science·2022
Same author

Pathogenesis of immune thrombocytopenia in common variable immunodeficiency.

Autoimmunity reviews·2020
Same author

Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?

Tumori·2019
Same author

Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.

Haematologica·2019
Same author

Calcium-Dependent Src Phosphorylation and Reactive Oxygen Species Generation Are Implicated in the Activation of Human Platelet Induced by Thromboxane A2 Analogs.

Frontiers in pharmacology·2018
Same author

Primary sphenoid lymphoma: Focus on imaging.

Tumori·2018

Area of Science:

  • Hematology
  • Immunology
  • Internal Medicine

Background:

  • Acquired blood coagulation inhibitors are immunoglobulins that impair clotting.
  • These inhibitors can neutralize specific clotting factors or accelerate their clearance.
  • This leads to an increased tendency for bleeding.

Purpose of the Study:

  • To review recent advances in nonhemophilic coagulation inhibitors.
  • Focus on autoantibodies in individuals without pre-existing coagulation defects.
  • To cover pathophysiology, diagnosis, and treatment of these rare bleeding disorders.

Main Methods:

  • Literature review of recent scientific publications.
  • Synthesis of current knowledge on acquired coagulation inhibitors.
  • Focus on nonhemophilic inhibitors and autoantibodies.

Related Experiment Videos

Main Results:

  • Recent advances in understanding the pathophysiology of autoantibody formation.
  • Improved diagnostic strategies for identifying specific inhibitors.
  • Emerging treatment options for acquired bleeding disorders.

Conclusions:

  • Nonhemophilic coagulation inhibitors represent rare but significant acquired bleeding disorders.
  • Continued research is crucial for refining diagnosis and treatment.
  • Understanding autoantibody mechanisms is key to managing these conditions.